l carnitine subcutaneous injection L-Carnitine Injections: A Clinical Guide for Practitioners L-Carnitine Injection | Levocarnitine IV

Clinical governance: If a practice elects to explore BPC-157, use informed consent

Esposito 2014

Neutralizing antibodies to tesamorelin and hGHRH were detected in vitro at Week 52 in 10% and 5% of tesamorelin-treated patients, respectively

Important upfront: in the Western pharmaceutical world BPC-157 never passed Phase 3 trials (= the large clinical trials required before drug approval)

Pale skin Heart palpitations Shortness of breath A smooth tongue Vision loss Constipation Loss of appetite Diarrhea Gas Vision loss Mental problems like depression, memory loss, or behavioral changes Nerve problems like numbness or tingling, muscle weakness, and problems walking